PURPOSE: Neutralization of IL-13 is an attractive approach for treatment of asthma. In this report, we developed a novel PK-PD model that described the relationship between the circulating concentrations of total IL-13 and a neutralizing anti-IL-13 antibody (Ab-02) in the model of acute airway inflammation induced by Ascaris challenge to cynomolgus monkeys, as well as in naive monkeys. METHODS: Cynomolgus monkeys were administered a single intravenous or subcutaneous dose of Ab-02. Total IL-13 and Ab-02 concentrations were measured by immunoassays. RESULTS: Modeling and simulations indicated that: (1) Ascaris challenge induced approximately three-fold increase in circulating IL-13 concentrations, when compared to naive animals, consistent with the notion that Ascaris-induced airway inflammation was IL-13-mediated; (2) the transient increase in total IL-13 concentrations observed in both naive and Ascaris-challenged monkeys following Ab-02 administration was due to the increase in Ab-02-bound IL-13, while free IL-13 was decreased; and (3) the extent and duration of neutralization of circulating IL-13 were different in naive and Ascaris-challenged monkeys for the same Ab-02 dose regimen. CONCLUSIONS: The PK-PD model presented in this report may be applied to study drug-ligand interactions when a free ligand cannot be directly assayed but total ligand concentrations are modulated by the drug administration.
PURPOSE: Neutralization of IL-13 is an attractive approach for treatment of asthma. In this report, we developed a novel PK-PD model that described the relationship between the circulating concentrations of total IL-13 and a neutralizing anti-IL-13 antibody (Ab-02) in the model of acute airway inflammation induced by Ascaris challenge to cynomolgus monkeys, as well as in naive monkeys. METHODS:Cynomolgus monkeys were administered a single intravenous or subcutaneous dose of Ab-02. Total IL-13 and Ab-02 concentrations were measured by immunoassays. RESULTS: Modeling and simulations indicated that: (1) Ascaris challenge induced approximately three-fold increase in circulating IL-13 concentrations, when compared to naive animals, consistent with the notion that Ascaris-induced airway inflammation was IL-13-mediated; (2) the transient increase in total IL-13 concentrations observed in both naive and Ascaris-challenged monkeys following Ab-02 administration was due to the increase in Ab-02-bound IL-13, while free IL-13 was decreased; and (3) the extent and duration of neutralization of circulating IL-13 were different in naive and Ascaris-challenged monkeys for the same Ab-02 dose regimen. CONCLUSIONS: The PK-PD model presented in this report may be applied to study drug-ligand interactions when a free ligand cannot be directly assayed but total ligand concentrations are modulated by the drug administration.
Authors: Meindert Danhof; Joost de Jongh; Elizabeth C M De Lange; Oscar Della Pasqua; Bart A Ploeger; Rob A Voskuyl Journal: Annu Rev Pharmacol Toxicol Date: 2007 Impact factor: 13.820
Authors: K Margolin; M S Gordon; E Holmgren; J Gaudreault; W Novotny; G Fyfe; D Adelman; S Stalter; J Breed Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: Andrea Bree; Franklin J Schlerman; Michael Wadanoli; Lioudmila Tchistiakova; Kimberly Marquette; Xiang-Yang Tan; Bruce A Jacobson; Angela Widom; Timothy A Cook; Nancy Wood; Suresh Vunnum; Rustem Krykbaev; Xin Xu; Debra D Donaldson; Samuel J Goldman; Joseph Sypek; Marion T Kasaian Journal: J Allergy Clin Immunol Date: 2007-03-26 Impact factor: 10.793
Authors: Jennifer Q Dong; David H Salinger; Christopher J Endres; John P Gibbs; Cheng-Pang Hsu; Brian J Stouch; Eunju Hurh; Megan A Gibbs Journal: Clin Pharmacokinet Date: 2011-02 Impact factor: 6.447